<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122560">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01730872</url>
  </required_header>
  <id_info>
    <org_study_id>12-270-0007</org_study_id>
    <nct_id>NCT01730872</nct_id>
  </id_info>
  <brief_title>Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model</brief_title>
  <official_title>A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ORA, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of the modified Conjunctival
      Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to
      treatment with a proven ocular anti-inflammatory medication,

      Prednisolone, assessed by the following measures:

      Chronic Allergic Inflammation assessed using confocal microscopy Ocular itching Conjunctival
      redness
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, single center, randomized, double-masked, placebo controlled study. Subjects
      will be randomized to one of the following treatment arms to dose four times per day (QID)
      for 4 days between Visits 3 and 4.

      Prednisolone phosphate Tears Naturale II Ophthalmic Solution (Placebo)

      Duration:

      Approximately 2 weeks

      Controls:

      Artificial Tears (Tears NaturaleÂ® II)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Inflammation</measure>
    <time_frame>90 minutes post CAC</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visit 3A compared to Visit 5A</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>3 minutes post CAC</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visit 3B compared to 5B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Redness</measure>
    <time_frame>7 minutes post-CAC</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visit 3B compared to 5B</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisolone Sodium Phosphate Ophthalmic Solution, 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tears Naturale II Ophthalmic Solution, 1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Sodium Phosphate Ophthalmic Solution 1%</intervention_name>
    <description>One drop in each eye, four times/day for 4 days.</description>
    <arm_group_label>Prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tears Naturale II Ophthalmic Solution</intervention_name>
    <description>one drop in each eye, four times/ day (QID) for 4 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age &amp; either sex, any race

          -  Willing and able to follow all instructions

          -  Positive history of ocular allergies

          -  Reproducible positive ocular allergic reaction induced by conjunctival
             allergen challenge

        Exclusion Criteria:

          -  Have planned surgery during trial period

          -  Female currently pregnant, planning a pregnancy or lactating

          -  Use of disallowed medications

          -  Have ocular infections, or ocular conditions that could affect study parameters

          -  Have moderate to severe dry eye

          -  Have used an investigational drug or device within 30 days of start of study

          -  Female that is currently pregnant, planning a pregnancy or lactating
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Medical Society, Alpha Omega Alpha Honor Society, American Academy of Ophthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 14, 2013</lastchanged_date>
  <firstreceived_date>November 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
